

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
SHUB	The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators	Biobanking	SHORE: Dr. Sandra Cottingham	Spectrum Health Biorepository david.chesla@spectrumhealth.org (616) 267-2629
2016-013	NMTRC-014	Treatment	SHORE: Dr. Deanna Mitchell	Mary Durston Mary.Durston@helendevoschildrens.org (616) 486-2051
	An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFN γ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis	Supportive Care	SHORE: Dr. Beth Kurt	Mary Durston Mary.Durston@helendevoschildrens.org (616) 486-2051
AGCT1531	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
AGCT1532	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1609 DART	Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

A221701	Alliance A221701, Phase III placebo-controlled trial to evaluate dexamethasone use for everolimus-induced oral stomatitis: prevention versus early treatment approaches: MIST (My Individualized Stomatitis Treatment)	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A231601CD	Improving Surgical Care and Outcomes in Older Cancer Patients through Implementation of An Efficient Pre-Surgical Toolkit (OPTI-surg)	Cancer Care Delivery	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A221602	Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double-Blind, Placebo-Controlled Trial	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
DCP-001	Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)	Screening	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
S1714	A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients	Quality of Life	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
URCC 18007	Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

WF-10217	Work Ability in Young Adult Survivors (WAYS)	Behavioral	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAZ171	Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy-induced peripheral neuropathy in African American Women	Supportive Care	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A231602CD	Assessing Financial Difficulty in Patients with Blood Cancers	Economics of Care	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
EAY131-MATCH Screening Trial	Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ASCO TAPUR	Targeted Agent and Profiling Utilization Registry Study: All Drugs Provided	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NCI PDM 9846	Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute	Biobanking	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
ACCRU 2018-01	Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors	Other	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

APEC1621	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Trial)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
2020-285	NCI COVID-19 In Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
Exact Sciences	Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from Twelve Primary Cancer Diagnoses: Breast, Lung, Colorectal, Prostate, Bladder, Uterine, Kidney, Renal, Pelvis, Pancreatic, Liver, Stomach, Ovarian, and Esophageal Cancer	Biobanking	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
STMW 2020.03	A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 www.chcwm.com
ALX148 (Alexo)	AT1488001: Phase I, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors or Lymphoma Examining Safety, Pharmacokinetics and Tolerability. Now in Combination Phase II with Pembrolizumab, Rituximab, and Trastuzumab	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

AVID-100	<i>AVID100-01: A Phase IA/IIA Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1 in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
APG-115	<i>APG-115 : A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Ascentage Pharma: 1252	<i>APG-1252-US-001: Phase I, Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or Other Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Ascentage Pharma: 1387	<i>APG-1387-US-001 : A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or in Combination with Systemic Anti-cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
BeiGene USA	<i>BGB-290-103: A Phase IB Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556

Bristol-Myers Squibb	<i>CA031002: A Phase I/II First-in-human Study of BMS-986258 (anti TIM3) Alone and in Combination with Nivolumab in Advanced Malignant Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
COM701-Compugen	<i>CPG-01-001: A Phase IA/IB Study of COM701 as Monotherapy and in Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
COM902-Compugen	<i>CPG-02-101: A Phase I Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Coordination Pharmaceuticals: 100	<i>CPI-CL18-001: A Phase I, First in Human Study Evaluation the Safety, Tolerability, and Pharmacokinetics of CPI-100 via Intravenous Infusion in Patients with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Coordination Pharmaceuticals: 200	<i>CPI-200CL01: A Phase I, First in Human Study Evaluation the Safety, Tolerability, and Pharmacokinetics of CPI-200 via Intravenous Infusion in Patients with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Exelixis	<i>XL092: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Ikena	<i>IK-175-001: A Phase I, Open-Label, Dose-Escalation, and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556

InhibRx-105	<i>INBRX-105: An Open-Label, Multicenter, First-in-human, Dose-Escalation Phase I Study of INBRX-105 in Subjects with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
InhibRx-106	<i>INBRX-106: An Open-Label, Multicenter, First-in-human, Dose-Escalation, Phase I Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
InhibRx-109	<i>INBRX-109: An Open-Label, Multicenter, First-in-human, Dose-Escalation, Phase I Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Innovent	<i>IBI188: A Phase IA Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-Cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients with Advanced Malignant Tumors and Lymphomas</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Klus	<i>KL264-01: A Phase I/II, First-in-human, Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are Refractory to Available Standard Therapies</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Expanded Access Loxo	<i>LOXO-RET-18037: A Multicenter Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556

MacroGenics-018	<i>MGC018-01: A Phase I/II, First-in-human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
MacroGenics-019	<i>MGD019: A Phase I, First-in-human, Open-Label, Dose-Escalation and Cohort Expansion Study of MGA019, a Bispecific DART Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Merck-5618	<i>MK-5618: A Phase IB Multicenter Clinical Study of Selumetinib (MK-5618) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Merck-8353	<i>MK-8353-013: A Phase IB Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Odonate	<i>ODO-TE-S101: An Open-label, Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Symphogen	<i>Sym021-01: A Phase I Open-Label, Multicenter Trial Investigating the Safety, Tolerability and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies or Lymphomas</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556

Syros	<i>SY-5609-101: A Phase I Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Selected Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
SCI-CD47-001	<i>HU5F9-G4 : First-in-human Phase I Dose-escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
R3767-ONC-1613	<i>REGN3767 : A Phase I, Open-label, Dose-escalation and Cohort Expansion First-in-human, Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (Anti-PD-1-mAb) in Patients with Advanced Malignancies</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
CP-MGA012-01	<i>MGA012 : A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
ASN003-101	<i>ASN003 : A Phase I, Open-label, Dose-finding, and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
5F9004	<i>Hu5F9-G4-Cetuximab : A Phase Ib/II Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
APX-CLN-0011	<i>A Phase I Study of APX3330 in Patients with Advanced Solid Tumors</i>	Treatment	START Midwest Investigators	START Midwest (616) 954-5556

CP-MGA271-03	Macrogenics Protocol CP-MGA271-03: A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and Other B7-H3-Expressing Cancers	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
CPI-0209	A Phase I/II Study of CPI-0209 Monotherapy in Combination with Other Therapy in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
Sym 021	Sym 021: A Phase 1, Open-Label, Multicenter Trial investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy and in Combination with either Sym022 (Anti-LAG-3) or SYM023 (Anti-TIM-3) in Patients with Advanced Solid Tumor Malignancies or Lymphomas	Treatment	START Midwest Investigators	START Midwest (616) 954-5556
eFT226	A Phase I-II Dose-escalation and Cohort-expansion of Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5556